Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

4 November 2024

Topic(s): Normative Guidance/Policies

Product(s): Cabotegravir, Dapivirine Vaginal Ring

Region(s): Sub-Saharan Africa

Countries: Eswatini

Type: Document

Download

Featured Resources

External Link

The WHO and Jhpiego Provider Training Toolkit on Use of Oral and Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

This toolkit is designed to help clinicians develop knowledge and skills to provide multiple HIV PrEP methods. The toolkit includes resources for oral PrEP, long-acting cabotegravir (CAB-LA), dapivirine vaginal ring (DVR), and long-acting lenacapavir (LEN).
External Link

Long-Acting PrEP Market Assessment for Key Populations: Global access and readiness report (2025)

This market assessment supports countries, donors, implementing partners, and advocates in making informed decisions about the introduction, scale-up, and equitable delivery of long-acting PrEP among key populations and other priority groups.
External Link

Global Forecast of Long-Acting PrEP Need for Key Populations (2025–2030)

This first-of-its-kind forecast estimates: 11.16 million person-years of PrEP needed annually by 2030 among MSM, TGW, FSW, and PWID Uptake scenarios for CAB-LA, LEN, and oral monthly PrEP Forecasts segmented by region, population group, and product Use it to guide: Procurement planning, donor alignment, and national scale-up targets.
External Link

Expanding Access to a Choice-Based HIV Prevention Market

This special JIAS supplement illustrates current evidence, implementation learnings and challenges associated with the introduction, uptake, and continued use of PrEP within the context of an expanded HIV prevention method-mix.
Presentation

Dapivirine Vaginal Ring Early Market Access Vehicle (EMAV)

In response to the voices of adolescent girls and women who need more HIV prevention choices, The Global Fund (GF) and the Children Investment Fund Foundation (CIFF) have partnered to make dapivirine vaginal rings available in GF-supported countries through an early market access vehicle. See here for EMAV request form in English. For guidance on…
External Link

A Mixed-Method Study of Feasibility and Acceptability of the Dapivirine Vaginal Ring among Adolescent Girls and Young Women (AGYW) in Selected Zimbabwean Districts

This article from PLOS Global Public Health describes the results of a study assessing the acceptability and feasibility of introducing the dapivirine vaginal ring (DVR) as an HIV prevention method among young women in Zimbabwe and to assess motivations and barriers of DVR uptake among the target population.
Spreadsheet

2024 Q4 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…
External Link

HIVR4P 2024 Knowledge Toolkit

The HIVR4P 2024 Knowledge Toolkit highlights important scientific advancements and innovative research across key thematic areas presented at the HIVR4P 2024 conference. Thematic areas include the PURPOSE 2 trial of long-acting lenacapavir for PrEP, data on the three-month dapivirine vaginal ring, and early evidence on offering a choice of PrEP methods.
External Link

Safety and Drug Quantification of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis in Breastfeeding Mother–Infant Pairs (MTN-043): A phase 3B, open-label, randomised trial

This article from The Lancet HIV discusses the results of the Microbicide Trials Network (MTN)-043 trial, which assessed the safety of use of the dapivirine vaginal ring during breastfeeding amongst participants in Malawi, South Africa, Uganda, and Zimbabwe.

MTN-020 ASPIRE

Archived from the MTN website before it was taken down. Archived MTN ASPIRE news page available here. Primary Objectives Determine the effectiveness of dapivirine (25 mg) administered in a silicone elastomer matrix vaginal ring (VR), when inserted once every 4 weeks, in preventing HIV-1 infection among healthy sexually active HIV-uninfected women Assess the safety of…